Calquence – which is a competitor to AbbVie ... in the first nine months of 2024 and is AZ's third-largest cancer product. In the same period, Imbruvica fell around 7% to $2.5 billion, while ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...

EMA committee recommends approval of AstraZeneca’s Calquence plus chemoimmunotherapy to treat adult patients with mantle cell lymphoma: Cambridge, UK Tuesday, April 1, 2025, 17: ...

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuster ...

Calquence in combination with bendamustine and rituximab has been recommended for approval in the European Union, EU, for ...

Calquence combo reduced disease progression or death risk by 27% in untreated mantle cell lymphoma. Learn how to trade volatility during Q1 earnings season, live with Matt Maley on Wednesday ...

AstraZeneca announced on Monday that it secured a US regulatory approval and a positive EU recommendation for two of its ...

and we think the company is developing several key products that hold blockbuster potential. In particular, the company's launched cancer drugs Tagrisso, Imfinzi, Lynparza, and Calquence are well ...

has reached a significant milestone as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended its drug Calquence (acalabrutinib) for approval ...

has reached a significant milestone as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended its drug Calquence (acalabrutinib) for approval in ...